B. Fernández-Rojas , T. Gómez-Sierra , O.N. Medina-Campos , J. Hernández-Juárez , P.A. Hernández-Cruz , I.B. Gallegos-Velasco , Y. Pérez-Cervera , J. Pedraza-Chaverri
{"title":"Antioxidant activity of glucosamine and its effects on ROS production, Nrf2, and O-GlcNAc expression in HMEC-1 cells","authors":"B. Fernández-Rojas , T. Gómez-Sierra , O.N. Medina-Campos , J. Hernández-Juárez , P.A. Hernández-Cruz , I.B. Gallegos-Velasco , Y. Pérez-Cervera , J. Pedraza-Chaverri","doi":"10.1016/j.crtox.2023.100128","DOIUrl":null,"url":null,"abstract":"<div><p>Glucosamine (GlcN) is the most used supplement for osteoarthritis treatment. <em>In vitro</em> studies have related GlcN to beneficial and detrimental effects on health. The aim of this study was to evaluate the effects of O-linked-N-acetylglucosaminylation (O-GlcNAc) on GlcN-induced ROS production and Nrf2 expression in human dermal microvascular endothelial cells-1 (HMEC-1) and to evaluate the antioxidant capacity of GlcN compared to well-known antioxidants. For this, we evaluate the antioxidant capacity by <em>in vitro</em> assays. Besides, the GlcN (5–20 mM) effects on cell viability, reactive oxygen species (ROS) production, O-GlcNAc, and nuclear factor erythroid-2-related factor 2 (Nrf2) expression with and without the O-GlcNAc inhibitor OSMI-1 (10 μM) in HMEC-1 were evaluated. GlcN showed high inhibitory concentration (low scavenging activity) against superoxide (O<sub>2</sub><sup>•─</sup>, IC<sub>20</sub> = 47.67 mM), 2,2-diphenyl-1-picrylhydrazyl (DPPH<sup>•</sup>, IC<sub>50</sub> = 21.32 mM), and hydroxyl (HO<sup>•</sup>, IC<sub>50</sub> = 14.04 mM) radicals without scavenging activity against hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and low antioxidant capacity determined by oxygen radical absorbance capacity (ORAC, 0.001 mM Trolox equivalent) and ferric reducing antioxidant power (FRAP, 0.046 mM Trolox equivalent). In cell culture, GlcN (20 mM) reduced cell viability up to 26 % and induced an increase in ROS production (up to 70 %), O-GlcNAc (4-fold-higher <em>vs.</em> control), and Nrf2 expression (56 %), which were prevented by OSMI-1. These data suggest an association between O-GlcNAc, ROS production, and Nrf2 expression in HMEC-1 cells stimulated with GlcN.</p></div>","PeriodicalId":11236,"journal":{"name":"Current Research in Toxicology","volume":"5 ","pages":"Article 100128"},"PeriodicalIF":2.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/82/main.PMC10558709.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666027X23000269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Glucosamine (GlcN) is the most used supplement for osteoarthritis treatment. In vitro studies have related GlcN to beneficial and detrimental effects on health. The aim of this study was to evaluate the effects of O-linked-N-acetylglucosaminylation (O-GlcNAc) on GlcN-induced ROS production and Nrf2 expression in human dermal microvascular endothelial cells-1 (HMEC-1) and to evaluate the antioxidant capacity of GlcN compared to well-known antioxidants. For this, we evaluate the antioxidant capacity by in vitro assays. Besides, the GlcN (5–20 mM) effects on cell viability, reactive oxygen species (ROS) production, O-GlcNAc, and nuclear factor erythroid-2-related factor 2 (Nrf2) expression with and without the O-GlcNAc inhibitor OSMI-1 (10 μM) in HMEC-1 were evaluated. GlcN showed high inhibitory concentration (low scavenging activity) against superoxide (O2•─, IC20 = 47.67 mM), 2,2-diphenyl-1-picrylhydrazyl (DPPH•, IC50 = 21.32 mM), and hydroxyl (HO•, IC50 = 14.04 mM) radicals without scavenging activity against hydrogen peroxide (H2O2) and low antioxidant capacity determined by oxygen radical absorbance capacity (ORAC, 0.001 mM Trolox equivalent) and ferric reducing antioxidant power (FRAP, 0.046 mM Trolox equivalent). In cell culture, GlcN (20 mM) reduced cell viability up to 26 % and induced an increase in ROS production (up to 70 %), O-GlcNAc (4-fold-higher vs. control), and Nrf2 expression (56 %), which were prevented by OSMI-1. These data suggest an association between O-GlcNAc, ROS production, and Nrf2 expression in HMEC-1 cells stimulated with GlcN.
氨基葡萄糖(GlcN)是治疗骨关节炎最常用的补充剂。体外研究表明GlcN对健康的有益和有害影响。本研究的目的是评估O-连接-N-乙酰氨基葡萄糖化(O-GlcNAc)对GlcN诱导的人真皮微血管内皮细胞-1(HMEC-1)中ROS产生和Nrf2表达的影响,并评估GlcN与已知抗氧化剂相比的抗氧化能力。为此,我们通过体外测定来评估抗氧化能力。此外,评估了在HMEC-1中使用和不使用O-GlcNAc抑制剂OSMI-1(10μM)的情况下,GlcN(5-20mM)对细胞活力、活性氧(ROS)产生、O-GlcNAc和核因子-红细胞2型相关因子2(Nrf2)表达的影响。GlcN对超氧化物(O2•─, IC20=47.67 mM)、2,2-二苯基-1-苦基肼(DPPH•,IC50=21.32 mM)和羟基(HO•,IC50=14.04 mM)自由基对过氧化氢(H2O2)没有清除活性,并且通过氧自由基吸收能力(ORAC,0.001 mM Trolox当量)和铁还原抗氧化能力(FRAP,0.046 mM Trooxy当量)确定的抗氧化能力低。在细胞培养中,GlcN(20mM)降低了高达26%的细胞活力,并诱导ROS产生(高达70%)、O-GlcNAc(比对照高4倍)和Nrf2表达(56%)的增加,这些都被OSMI-1阻止。这些数据表明,在GlcN刺激的HMEC-1细胞中,O-GlcNAc、ROS产生和Nrf2表达之间存在关联。